ArticleCureus2025
Assessment of Treatment Response in Patients With Diffuse Large B-cell Non-Hodgkin Lymphoma Using the Deauville Criteria: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent subtype of non-Hodgkin lymphoma in the adult population and is typically associated with an aggressive clinical trajectory. Despite significant therapeutic advancements, a proportion of patients exhibit resistance to first-line chemotherapy, underscoring the need for accurate and early assessment of treatment response to inform prognosis and optimize therapeutic strategies. We describe the case of a 64-year-old male with a medical history notable for ischemic heart disease and metabolic syndrome who presented with abdominal pain and unintentional weight loss. Diagnostic evaluation confirmed a diagnosis of DLBCL, with initial F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), revealing extensive nodal and extranodal disease involvement. Following the completion of six cycles of frontline chemotherapy, end-of-treatment FDG-PET/CT demonstrated substantial resolution of metabolic activity, corresponding to a Deauville score of 2, consistent with a complete metabolic response. The Deauville five-point scoring system is a standardized method for interpreting PET/CT scans in lymphoma, comparing lesion uptake to the mediastinum and liver to assess treatment response. Consequently, no additional consolidation therapy was pursued. This case illustrates the pivotal role of FDG-PET/CT, interpreted using the Deauville five-point scale, as a reliable and clinically relevant modality for evaluating treatment response in DLBCL, thereby facilitating informed decision-making regarding the continuation or cessation of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.